Note: The following article concerns a 2006 guidance from the FDA, which purported to affect the way preclinical drug testing is carried out. As noted, I am interested in this subject, and I'd like to do so more work on it, regarding, for example, how this matter is affected by the notice of proposed rulemaking concerning the federal Common Rule concerning human subjects research.

Given recent developments, I am not sure I will post this on the Social Sciences Research Network (SSRN). However, I am not entirely satisfied with the way the footnotes are produced on this blogger website. If any scholars have suggestions, I'd be gratified to hear from you. My email address is on the blog.